Happy Monday! The latest episode of Tox in Ten ACMT Highlights is live! @gillianbchum sits down with @macacharya to discuss the role of artificial intelligence in medical toxicology
@acmtmedtox https://t.co/mfsd4CxdRO
The best way to spend your Monday is listening to the newest @ToxInTen episode! @gillianbchum sits down with @macacharya to discuss the role of artificial intelligence in medical toxicology. #ToxTwitter#MedTwitter
Dear friends of @eapcct
This week #toxreadingcorner is on “The Role and Promise of Artificial Intelligence in Medical Toxicology” by Michael A. Chary et al. https://t.co/Vnz75tVwcc @macacharya @ManiniAlex @PEMTox
Toxicology 2.0 symposium, now speaking: The geospatial and linguistic dynamics of conversations on Twitter about vaping. Michael Chary (2020 -Abstract 099) #EAPCCT2021@macacharya
#2021ACMT Happening now: @macacharya shines a light on the role artificial intelligence can play in medical toxicology during his 2:30 PM talk. @WeillCornell
Here's the @Brief_19 Week in Review for COVID-19 research!
Take three minutes and catch up on the must know stories from the frontline this week.
Expertise from @angie_rasmussen @JPBelinkieMD @macacharya
https://t.co/CnSx9VJO6I via @Brief_19
In @Brief_19 later this AM:
✔️Analysis on the new Moderna trial. One dose? Promising but by no means ready for prime time. With @macacharya
✔️Will vaccine hesitancy lead to vaccine mandates? Schools will be a major battleground. @JPBelinkieMD explains.
https://t.co/4wRvUc85gS
Our latest paper in Toxicology Communications: Early intravenous lipid emulsion therapy for diphenhydramine overdose: a case report.
https://t.co/nZUO64xcH9
Latest articles in Toxicology Communications (2/2):
Early intravenous lipid emulsion therapy for diphenhydramine overdose: a case report.
https://t.co/cBr3Dyh5YQ
From Clemons et al of @KendallRMC and @macacharya of
@WeillCornell@ED_WCMC@WCMEmergency
Back in June, @macacharya wrote a brief on a small trial of colchicine in Covid-19 for @Brief_19.
The results were promising.
New findings publicized via press release (COLCORONA trial) are far too vague to be useful.
But here's what we do know...
👇
https://t.co/bWZ44SATE4
Daily briefings from @Brief_19 return tomorrow AM!
This week: frontline expertise on the latest in Covid-19 medical research from @bernardchangMD@sampx@macacharya and @JPBelinkieMD.
Written by docs *for everyone*
Subscribe free and get it first! 🙌
https://t.co/4wRvUc85gS
BinaxNOW Antigen Testing Can Be Used In Asymptomatic Individuals. Is It Ready For Prime Time?
First, we must ask the right question...
https://t.co/tG828BouKr via @Brief_19@macacharya
Abbott's new rapid antigen test, BinaxNOW, has received EUA from the @US_FDA.
@macacharya on a new @CDCgov study evaluating use in asymptomatic individuals & what this means:
https://t.co/30w4a9Kq0U
<Breaking>
Moderna vaccine trial has been published.
Our immediate analysis here, with updates in our AM briefing.
https://t.co/n5xEE4hy4c via @Brief_19@macacharya